Drug Trial Radar · NCT03484923
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Sep 10, 2018
Primary completion
Dec 30, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Conditions
- Melanoma
Interventions
PDR001Drug
400 mg of PDR001 administered every 4 weeks intravenously
LAG525Drug
600 mg of LAG525 administered every 4 weeks intravenously
INC280Drug
400 mg of INC280 administered twice daily orally
ACZ885Drug
200 mg of ACZ885 administered every 4 weeks subcutaneosuly
LEE011Drug
600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 49 months (randomized section) and 18 months (non-randomized section)
Locations
30 sites in 10 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute
Los Angeles, California
University of California Los Angeles
Los Angeles, California
UCSF Medical Center .
San Francisco, California
Massachusetts General Hospital Massachusetts Gen. Hospital CC
Boston, Massachusetts
NYU Laura and Isaac Perlmutter Cancer Center Perlmutter Cancer Center
New York, New York
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Novartis Investigative Site
North Sydney, New South Wales, Australia
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Rotterdam, Netherlands
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Catalonia, Spain
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Manchester, United Kingdom
Novartis Investigative Site
Northwood, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.